Hantz Financial Services’s Solid Biosciences SLDB Stock Holding History

Hantz Financial Services’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10K	Hold	1,000	–	–	﹤0.01%	2087
2026 Q1	$7K	Hold	1,000	–	–	﹤0.01%	2122
2025 Q4	$6K	Hold	1,000	–	–	﹤0.01%	2119
2025 Q3	$6K	Hold	1,000	–	–	﹤0.01%	1981
2025 Q2	$5K	Hold	1,000	–	–	﹤0.01%	1765
2025 Q1	$4K	Hold	1,000	–	–	﹤0.01%	1232
2024 Q4	$4K	Hold	1,000	–	–	﹤0.01%	930
2024 Q3	$7K	Hold	1,000	–	–	﹤0.01%	838
2024 Q2	$6K	Hold	1,000	–	–	﹤0.01%	847
2024 Q1	$13K	Buy	1,000 +334	+50%	+$3.13K	﹤0.01%	800
2023 Q4	$4K	Buy	+666	New	+$2.13K	﹤0.01%	955

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Hantz Financial Services's SLDB Position: Q2 2026 in Review

Hantz Financial Services held its Solid Biosciences (SLDB) position steady in Q2 2026 at 1,000 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #2087.

Hantz Financial Services first reported a position in SLDB in Q4 2023 and has held it in 11 quarters since. The position peaked at $13K in Q1 2024. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Hantz Financial Services held 1,000 shares of Solid Biosciences worth $10K as of Q2 2026.
Hantz Financial Services left its Solid Biosciences share count unchanged in Q2 2026.
Solid Biosciences made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #2087 holding.
Hantz Financial Services first reported a position in Solid Biosciences in Q4 2023 and has held it in 11 quarters since.
Hantz Financial Services's Solid Biosciences position peaked at $13K in Q1 2024.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.